YIBAI PHARMACEUTICAL: Children's cough syrup resumes production and sales

YIBAI PHARMACEUTICAL announced the resumption of production and sales of its children's cough syrup. The product was suspended from production in August 2025 due to a notice from the Guizhou Provincial Drug Administration, and the suspension was lifted on September 16, 2025, after rectification. From 2021 to 2024, the operating revenues of this product were 3.42 million yuan, 4.32 million yuan, 8.38 million yuan, and 1.51 million yuan, accounting for a small proportion of the company's total revenue. The impact of resuming production and sales on the company's performance is expected to be minimal

The A-share traditional Chinese medicine sector rapidly surged, with Xintian Pharma hitting the limit up, and YIBAI PHARMACEUTICAL, Zhendong Pharmacy, ZHONGSHENGYAOYE, Hansen Pharmaceutical, and ENWEI PHARMACEUTICAL following suit

YIBAI PHARMACEUTICAL: Loss of 19.9021 million yuan in the first half of the year

On the evening of August 20, YIBAI PHARMACEUTICAL disclosed its semi-annual report for 2025. The company achieved operating revenue of 993 million yuan in the first half of the year, a year-on-year decrease of 14.99%; the net profit attributable to the parent company was a loss of 19.9021 million yuan, compared to a loss of 106 million yuan in the same period last year. During the reporting period, the sales of the company's main products decreased, but the amount of cost expenses still exceeded the revenue amount; compared to the same period last year, due to the company's strengthened expense control and enhanced cost reduction and efficiency improvement, the decrease in cost expenses was greater than the decrease in revenue, resulting in a reduction in the current period's loss

A-share pharmaceutical stocks continue to adjust, CheezhengTTM approaches the limit down, and multiple stocks such as Xintian Pharmaceutical, Hanyu Pharmaceutical, Guilin Sanjin, Foci Pharmaceutical, YIBAI PHARMACEUTICAL, Zhendong Pharmacy, and Cosunter have fallen over 5%

YIBAI PHARMACEUTICAL received the "Notice of Suspension of Production and Sales" from the Guizhou Provincial Drug Administration

YIBAI PHARMACEUTICAL received a "Notice of Suspension of Production and Sales" from the Guizhou Provincial Drug Administration, due to the discovery of defects during inspection, requiring an immediate suspension of the production and sales of the children's cough syrup. The revenue contribution of this product from 2021 to 2024 is relatively small, and it is expected that this suspension will not have a significant impact on the company's performance